abstract |
The invention belongs to pharmaceutical technology, in particular to a kind of miRNA inhibitor is preparing the application in anti-tubercle bacillus drugs, further relates to a kind of anti-tubercle bacillus drugs.Inventor confirms that miR-27a antagomir can reduce the Intracellular survival after tubercle bacillus affection macrophage by a series of experiments;Relevant animal the experimental results showed that, miR-27a antagomir can effectively mitigate the pathology damage of lung, and can be substantially reduced the lotus bacterium amount of intrapulmonary tulase.The present invention provides this miRNA inhibitor of miR-27a antagomir to prepare the new application in anti-tubercle bacillus drugs, obviously, miR-27a antagomir can effectively inhibit the infection of tulase, be conducive to provide effective drug support for treatment lungy, to have wide potential applicability in clinical practice. |